Karina Kulangara

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Nanotopography-induced changes in focal adhesions, cytoskeletal organization, and mechanical properties of human mesenchymal stem cells

Evelyn K. F. Yim, Eric M. Darling, Karina Kulangara et al. · Biomaterials · 2009 · 707 citations · Full text

Natural Sciences, Biomedical Sciences, Cell Biology +16

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach, Nancy R. Zhang, Ellie Corigliano et al. · Applied immunohistochemistry & molecular morphology · 2016 · 353 citations · Full text

Medicine, Oncology, Pathology +17

Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid

Karina Kulangara, Katia Antoniello, Henry Markram · Proceedings of the National Academy of Sciences · 2007 · 295 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17